RecruitingPhase 2NCT06189833

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

Studying Multiple myeloma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Stichting European Myeloma Network
Intervention: Daratumumab(drug)
Enrollment: 200 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2023 – 2025

Study locations (30)

Innsbruck Medical University, Innsbruck, Austria
Ordensklinikum Linz, Linz, Austria
Clinic Ottakring, Vienna, Austria
Medical University of Vienna, Vienna, Austria
Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany
Klinikum rechts der Isar (MRI) der Technischen Universität München Department of Internal Medicine III (Hematology/Oncology) Munchen, München, Germany
University Hospital of Alexandroupolis, Alexandroupoli, Greece
Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens, Greece
St Savvas Cancer Hospital, Athens, Greece
Theagenion Cancer Hospital, Thessaloniki, Greece
AOU Ospedali Riuniti di Ancona, Ancona, Italy
ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
A.O.U. di Bologna - Policlinico S. Orsola Malpighi, Bologna, Italy
A.O.Spedali Civili di Brescia, Brescia, Italy
A.O.U. Careggi - Firenze, Florence, Italy
+15 more locations on ClinicalTrials.gov

Collaborators

Janssen Pharmaceutica

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06189833 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials